Investor Presentation

Date: November 03, 2026 BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Earnings Call Presentation of the Company Pertaining to the quarter and half year ended September 30, 2026 Dear Sir/Ma’am In continuation with the Company’s letter dated October 30, 2026, pertaining to intimation of schedule of earnings call to be held on Wednesday, November 04, 2026, at 12:30 PM (IST) and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the earnings presentation on the Unaudited Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026. The same is also available on the Company’s website at https://anthembio.com/ We request you to kindly take the same on record. Thanking you, Yours truly, For Anthem Biosciences Limited (Formerly known as Anthem Biosciences Private Limited) Divya Prasad Company Secretary & Compliance Officer Membership No: A41438 Anthem Biosciences Limited Investor Presentation November 3, 2026 Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute “forward-looking statements”. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Consolidated Profit & Loss Statement: Q2FY27 vs Q2FY26 vs Q1FY27 Performance Particulars (₹ Mn) Q2FY27 Q2FY26 YoY Q1FY27 QoQ FY26 Revenue from Operations 5,940 5,505 7.9% 4,182 42.0% 21,293 CRDMO 5,093 4,662 9.2% 3,408 49.4% 17,775 Specialty Ingredients 848 843 0.6% 774 9.5% 3,518 Other Income 589 478 23.3% 249 136.6% 1,508 Total Revenues 6,529 5,983 9.1% 4,431 47.4% 22,801 Cost of materials consumed and changes in inventories 1,847 2,234 -17.3% 1,462 26.3% 8,123 Employee benefits expense 813 672 20.9% 788 3.1% 2,812 Other expenses 566 415 36.2% 426 32.8% 1,969 EBITDA 3,304 2,661 24.1% 1,755 88.3% 9,896 EBITDA Margins 50.6% 44.5% 610 bps 39.6% 1,100 bps 43.4% Finance cost 33 31 8.3% 9 273.0% 71 Depreciation and amortization expense 307 335 -8.3% 300 2.4% 1,341 Profit before tax 2,964 2,296 29.1% 1,446 105.0% 8,486 Total tax expense 849 562 51.2% 246 244.6% 2,324 Profit after tax 2,115 1,734 21.9% 1,199 76.3% 5,917 Q2FY27 Consolidated Financial Highlights Revenues (₹ Mn) EBITDA1 (₹ Mn) and EBITDA Margins (%age) PAT (₹ Mn) and PAT Margins (%age) 5,505 5,940 44.5% 50.6% 29.0% 32.4% 40.0% 30.0% 20.0% 10.0% 3,304 0.0% 2,661 2,115 1,734 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 PBT (₹ Mn) and PBT Margins (%age) Net Cash (₹ Mn) Specialty Ingredients 14.3% 38.4% 45.4% Q2FY27 2,964 Revenue 2,296 Split 17,197 15,380 CRDMO 85.7% Q2FY26 Q2FY27 June 30, 2026 Sept 30, 2026 Note: 1. EBITDA for Q2FY27 includes Other Income of INR 588.98 Mn(Other Operating Income o/a of forex gain (net) 57.54 Mnand Financial / Non Operating Income of INR 531.45 Mn). Corresponding figures for Q2FY26 was Other Income of INR 477.53 Mn(Other Operating Income o/a of forex gain (net) INR 303.40 Mnand Financial / Non Operating Income of INR 174.13 Mn) Growth accelerated in Q2FY27, yielding robust financial performance and highest ever margins ₹5,940 Mn 50.6% 32.4% Strong Business Q2FY27 Revenues Q2FY27 EBITDA Margin Q2FY27 PAT Margin Performance 2,344 / 1,173 425KL 142KL Robust Technology # Employees / Scientific Staff Custom Synthesis Capacity Fermentation Capacity and Infrastructure 26.8%/50.3% 1.55x 1.16x Strong Returns and ROE / Q2FY27 Post Tax ROCE Q2FY27 Gross Fixed Assets Turnover Net Cash / Q2FY27 EBITDA* Balance Sheet *Based on Annualised EBITDA Consolidated Profit & Loss Statement: H1FY27 vs H1FY26 Performance Particulars (₹ Mn) H1FY27 H1FY26 YoY FY26 Revenue from Operations 10,123 10,914 -7.2% 21,293 CRDMO 8,501 9,195 -7.6% 17,775 Specialty Ingredients 1,622 1,718 -5.6% 3,518 Other Income 838 699 19.9% 1,508 Total Revenues 10,960 11,613 -5.6% 22,801 Cost of materials consumed and changes in inventories 3,309 4,542 -27.2% 8,123 Employee benefits expense 1,601 1,391 15.1% 2,812 Other expenses 992 875 13.4% 1,969 EBITDA 5,059 4,805 5.3% 9,896 EBITDA Margins 46.2% 41.4% 480 bps 43.4% Finance cost 42 47 -11.0% 71 Depreciation and amortization expense 607 599 1.3% 1,341 Profit before tax 4,410 4,159 6.0% 8,486 Total tax expense 1,096 1,066 2.8% 2,324 Profit after tax 3,314 3,092 7.2% 5,917 H1FY27 Consolidated Financial Highlights Revenues (₹ Mn) EBITDA2 (₹ Mn) and EBITDA Margins (%age) PAT (₹ Mn) and PAT Margins (%age) 10,914 41.4% 46.2% 10,123 26.6% 30.2% 5,059 0.0% 4,805 3,314 3,092 H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 PBT (₹ Mn) and PBT Margins (%age) Net Cash (₹ Mn) Specialty 35.8% 40.2% Ingredients 01234 .0000 0.... 0000 %%%%% 16.0% 4,410 4,159 H1FY27 Revenue 15,380 Split CRDMO 9,931 84.0% H1FY26 H1FY27 Sept 30, 2025 Sept 30, 2026 Note: 2. EBITDA for H1FY27 includes Other Income of INR 837.87 Mn(Other Operating Income o/a of forex gain (net) 70.22 Mnand Financial / Non Operating Income of INR 767.65 Mn). Corresponding figures for H1FY26 was Other Income of INR 699.08 Mn(Other Operating Income o/a of forex gain (net) INR 340.39 Mnand Financial / Non Operating Income of INR 358.69 Mn) Financial performance continues to remain strong with robust return profile for H1FY27 ₹10,123 Mn 46.2% 30.2% Strong Business H1FY27 Revenues H1FY27 EBITDA Margin H1FY27 PAT Margin Performance 65.3% 15 + 9 8.1% Platforms across Commercial Molecules Commercial + R&D Services discovery to Contribution to Revenues Late Stage (Phase III) Molecules Contribution to Revenues commercialization 21.0% / 39.3% 1.32x 1.52x Strong Returns and ROE / H1FY27 Post Tax ROCE H1FY27 Gross Fixed Assets Turnover Net Cash / H1FY27 EBITDA* Balance Sheet *Based on Annualised EBITDA Financial Highlights: Q2FY27 and H1FY27 Quarterly Performance:  Consolidated Revenue from Operations was ₹5,940 Mn for the quarter  CRDMO business delivered ₹5,093 Mn revenues  Specialty Ingredients delivered ₹848 Mn revenues  EBITDA was ₹3,304 Mn, with EBITDA margins at 50.6%  PAT (Profit After Tax) was ₹2,115 Mn, with PAT margins at 32.4% Half Year Performance:  Consolidated Revenue from Operations was ₹10,123 Mn for the half year  CRDMO business delivered ₹8,501 Mn revenues  Specialty Ingredients delivered ₹1,622 Mn revenues  EBITDA was ₹5,059 Mn, with EBITDA margins at 46.2%  PAT (Profit After Tax) was ₹3,314 Mn, with PAT margins at 30.2%  Net Cash position as of Sept 30, 2026, is ₹15,380 Mn Message from Chairman, MD and CEO “We are pleased to report a robust performance for Q2FY27, driven by our CRDMO revenue stream. Underlying demand continues to remains strong and we are confident in our ability to sustain growth and create long-term value for all stakeholders We expanded our EBITDA and PAT margins year-on-year. By maintaining strict discipline around cost efficiencies, yield optimization, and workforce productivity, we have further soli [Showing first 8,000 characters — download PDF for full document]